Recorded at 2017 AAHCM Annual Meeting
New Oral Anticoagulants Provide Another Option to Treat Venous Thromboembolism and Atrial Fibrillation in Home Patients
Venous thromboembolism (VTE) disease includes deep vein thrombosis and pulmonary embolism. Death from VTE in the United States is up to 100,000 persons annually. Atrial fibrillation (AF) is present in 2.7-6.1 million people in the US. This session will discuss evidence based treatment guidelines for VTE and AF along with the pharmacologic principles of available oral anticoagulants. Specific patient characteristics and co-morbidities that influence treatment options will be identified, including elements specific to the home patients, to achieve optimal outcomes. Pipeline medications for oral anticoagulation therapy will be introduced.